History of Neuropeptide Y

Category	Research
Also known as	NPY history, Tatemoto neuropeptide Y
Last updated	2026-04-14
Reading time	3 min read
Tags	historynpyneuropeptidesappetitesympathetic-nervous-system

Overview

Neuropeptide Y (NPY) is a 36-amino-acid peptide identified in 1982 by Kazuhiko Tatemoto, Mikko Carlquist, and Viktor Mutt at the Karolinska Institute, using a novel chemical assay to detect peptides with amidated C-termini. It shares sequence and structural features with peptide YY and pancreatic polypeptide, together forming the NPY family.

NPY is one of the most abundant and widely distributed neuropeptides in the vertebrate brain. It is particularly concentrated in the hypothalamus, where it is a key regulator of feeding and energy balance, and in sympathetic postganglionic neurons, where it is co-released with norepinephrine to modulate cardiovascular function. The peptide acts through multiple Y-type G protein-coupled receptors (Y1, Y2, Y4, Y5, Y6 in some species), each with distinct tissue expression patterns and pharmacology.

NPY is one of the most potent orexigenic peptides known. Injection into the hypothalamus of experimental animals produces robust food intake, particularly of carbohydrate-rich meals. In the central melanocortin system, NPY neurons co-express agouti-related peptide (AgRP) and oppose the anorexigenic effects of pro-opiomelanocortin-derived alpha-MSH.

Key People

Kazuhiko Tatemoto: First author of the NPY discovery paper.
Viktor Mutt (1923–1998): Long-time leader of the Karolinska neuropeptide program.
Tomas Hökfelt: Swedish neuroscientist who mapped NPY distribution in the nervous system.
Stephen R. Bloom: British endocrinologist who contributed to NPY and related gut peptide research.

Timeline

1982: NPY is isolated and sequenced.
1984: Distribution mapping shows NPY as one of the most abundant brain neuropeptides.
1986: NPY shown to powerfully stimulate food intake when injected into the hypothalamus.
1990s: Y receptors (Y1, Y2, Y4, Y5) are cloned.
2000s: NPY is implicated in stress, anxiety, and post-traumatic stress disorder.
2010s–2020s: Y-receptor-selective agents explored for obesity, hypertension, epilepsy, and mood disorders.

Background

The NPY/PYY/PP family is highly conserved across vertebrates, suggesting deep evolutionary importance. NPY neurons in the arcuate nucleus of the hypothalamus respond to circulating hormones including leptin, insulin, ghrelin, and PYY. When energy stores are low, NPY/AgRP neurons fire more, driving hunger and conserving energy. When leptin and insulin signals are high, NPY/AgRP activity is suppressed and POMC neurons are activated.

In the sympathetic nervous system, NPY contributes to vasoconstriction and has been implicated in cardiovascular stress responses. In the amygdala and hippocampus, NPY modulates anxiety and stress resilience, making it a candidate for neuropsychiatric therapies.

Modern Relevance

Y-receptor pharmacology offers a route to therapies in several domains. Y1 and Y5 antagonists have been studied for obesity, Y2 agonists as satiety agents, Y4 ligands for metabolic disease, and NPY itself (intranasal) for stress-related disorders. The same family underlies successful work on PYY-based obesity therapies. An NPY analog, velneperit, advanced to clinical trials for obesity, as did several other Y-receptor-targeting agents.

NPY is also an important biomarker and therapeutic target in certain pediatric cancers. Neuroblastoma and Ewing sarcoma express NPY and Y receptors, and these interactions may be exploited for imaging or therapy. The broad distribution and strong conservation of the NPY system keep it relevant across modern neuroscience, endocrinology, and oncology. For related topics, see leptin-discovery and pyy-discovery.